Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

v3.22.0.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Series B Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2019 $ 9 $ 226,524 $ (46) $ (217,070) $ 9,417
Balance, at beginning (in shares) at Dec. 31, 2019 8,531,504        
Issuance of common stock in exchange for exercise of warrants in February and March 2020 ($0.57 per share) $ 13 7,461 7,474
Issuance of common stock in exchange for exercise of warrants in February and March 2020 ($0.57 per share) (in shares)   13,111,999        
Deemed dividend in connection with repricing of November 2019 warrants 451 451
Warrant deemed dividend (451) (451)
Issuance of Series B Convertible preferred stock and common stock warrants in February 2020 ($1,000.00 per share, net of transactional expenses of $711) 4,602 4,602
Issuance of series B convertible preferred stock and common stock warrants in February 2020 ($1,000.00 per share, net of transactional expenses of $711) (in shares) 5,313          
Beneficial conversion feature in connection with issuance of Series B Convertible preferred stock 1,260 1,260
Preferred stock deemed dividend (1,260) (1,260)
Issuance of common stock and common stock warrants in February 2020 net of transactional expenses of $292 $ 4 1,891 1,895
Issuance of common stock and common stock warrants in February 2020 net of transactional expenses of $292 (in shares)   3,837,000        
Issuance of common stock upon conversion of Series B Convertible preferred stock $ 9 (9)
Issuance of common stock upon conversion of Series B convertible preferred stock (in shares) (5,313) 9,321,053        
Issuance of common stock in March 2020 net of transactional expenses of $1,221 $ 14 14,770 14,784
Issuance of common stock in March 2020 net of transactional expenses of $1,221(in shares)   14,550,000        
Issuance of common stock in June 2020 under the equity line $ 1 277 278
Issuance of common stock in June 2020 under the equity line (in shares)   464,471        
Issuance of common stock under At-the-market offering, net of transaction expenses of $2,304 $ 102 68,700 68,802
Issuance of common stock under At-the-market offering, net of transactional expenses of $2,304 (in shares)   102,676,174        
Issuance of common stock in the acquisition of Trigemina assets $ 2 1,358 1,360
Issuance of common stock in the acquisition of Trigemina assets (in shares)   2,000,000        
Issuance of common stock in July 2020 net of transactional expenses of $829 $ 21 9,620 9,641
Issuance of common stock in July 2020 net of transactional expenses of $829 (in shares)   20,940,000        
Issuance of common stock in exchange for exercise of warrants in July and August 2020 (see note 13) $ 5 2,417 2,422
Issuance of common stock in exchange for exercise of warrants in July and August 2020 (see note 13) (in shares)   4,533,404        
Issuance commitment under 2020 Purchase Agreement
Issuance of commitment shares under 2020 Purchase Agreement (in shares)   600,000        
Issuance of common stock under 2020 Purchase Agreement $ 26 14,548 14,574
Issuance of common stock under 2020 Purchase Agreement (in shares)   25,441,500        
Employee stock purchase plan 2 2
Employee stock purchase plan (in shares)   1,578        
Stock-based compensation 2,876 2,876
Foreign currency transaction loss (16) (16)
Net loss (50,463) (50,463)
Ending balance, value at Dec. 31, 2020 $ 206 355,037 (62) (267,533) 87,648
Balance, at end (in shares) at Dec. 31, 2020 206,008,683        
Issuance of common stock in January 2021($0.80 per share), net of transactional expenses of $3,096 $ 50 36,854 36,904
Issuance of common stock in January 2021 ($0.80 per share), net of transactional expenses of $3,096 (in shares)   50,000,000        
Issuance of common stock in exchange for exercise of warrants in March 2021 ($0.57 per share) 2 2
Issuance of common stock in exchange for exercise of warrants in March 2021 ($0.57 per share) (in shares)   3,400        
Issuance of common stock in February 2021($1.20 per share), net of transactional expenses of $5,002 $ 58 64,939 64,997
Issuance of common stock in February 2021 ($1.20 per share), net of transactional expenses of $5,002 (in shares)   58,333,334        
Issuance of common stock under At-the-market offering, net of transactional expenses of $2,332 $ 111 69,181 69,292
Issuance of common stock under At-the-market offering, net of transactional expenses of $2,332 (in shares)   110,248,449        
Issuance of common stock under 2021 Purchase Agreement, net of transactional expenses of $75 $ 65 41,131 41,196
Issuance of common stock under 2021 Purchase Agreement, net of transactional expenses of $75 (in shares)   64,539,361        
Issuance of commitment shares under 2021 Purchase agreement
Issuance of commitment shares under 2021 Purchase Agreement (in shares)   1,280,000        
Issuance of common stock in the acquisition of the OyaGen license $ 3 2,997 3,000
Issuance of common stock in the acquisition of the OyaGen license (in shares)   2,752,294        
Issuance of commitment shares under Lincoln park Purchase agreement $ 3 (3)
Issuance of commitment shares under Lincoln park Purchase agreement ( in shares)   2,909,091        
Employee stock purchase plan 96 96
Employee stock purchase plan (in shares)   170,952        
Stock-based compensation 7,899 7,899
Foreign currency transaction loss (30) (30)
Net loss (92,287) (92,287)
Ending balance, value at Dec. 31, 2021 $ 496 $ 578,133 $ (92) $ (359,820) $ 218,717
Balance, at end (in shares) at Dec. 31, 2021 496,245,564